Published in Oncotarget on July 30, 2014
Methylated circulating tumor DNA in blood: power in cancer prognosis and response. Endocr Relat Cancer (2016) 0.88
JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor. Oncotarget (2015) 0.78
Mouse models of liver cancer: Progress and recommendations. Oncotarget (2015) 0.77
Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding. Sci Rep (2015) 0.75
Cancer-associated oxidoreductase ERO1-α drives the production of VEGF via oxidative protein folding and regulating the mRNA level. Br J Cancer (2016) 0.75
Targeting tumor vasculature through oncolytic virotherapy: recent advances. Oncolytic Virother (2015) 0.75
Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. Oncotarget (2017) 0.75
Human basonuclin 2 up-regulates a cascade set of interferon-stimulated genes with anti-cancerous properties in a lung cancer model. Cancer Cell Int (2017) 0.75
Hydrogen sulfide acts as a double-edged sword in human hepatocellular carcinoma cells through EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways. Sci Rep (2017) 0.75
Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection. Sci Rep (2017) 0.75
Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy. Oncotarget (2017) 0.75
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol (2002) 7.23
Origin and function of myofibroblasts in kidney fibrosis. Nat Med (2013) 4.55
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol (2000) 2.10
HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol (2011) 2.10
Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol (2001) 2.02
Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res (2007) 1.80
Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer (2001) 1.75
Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res (2003) 1.54
Spontaneous tumour rupture and prognosis in patients with hepatocellular carcinoma. Br J Surg (2002) 1.53
Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer (2007) 1.50
Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol (2003) 1.45
The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res (2000) 1.43
Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res (2003) 1.42
Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem (2007) 1.37
Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol (2001) 1.34
Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics (2000) 1.33
Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer (2012) 1.32
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther (2009) 1.26
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res (2000) 1.25
Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology (2006) 1.20
Antiangiogenic gene therapy. Proc Natl Acad Sci U S A (1998) 1.18
Molecular genetics of hepatocellular neoplasia. Am J Transl Res (2010) 1.16
Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res (2003) 1.14
Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol (2008) 1.13
Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget (2013) 1.05
XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol (2004) 1.05
Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses. Oncogene (2006) 1.04
Frequent alteration of XAF1 in human colorectal cancers: implication for tumor cell resistance to apoptotic stresses. Gastroenterology (2007) 1.01
Isorhapontigenin (ISO) inhibited cell transformation by inducing G0/G1 phase arrest via increasing MKP-1 mRNA Stability. Oncotarget (2014) 0.99
A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget (2014) 0.97
XAF1 as a prognostic biomarker and therapeutic target in pancreatic cancer. Cancer Sci (2009) 0.97
Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer Gene Ther (2008) 0.93
X-linked inhibitor of apoptosis (XIAP) and XIAP-associated factor-1 expressions and their relationship to apoptosis in human hepatocellular carcinoma and non-cancerous liver tissues. Oncol Rep (2007) 0.93
p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells. Am J Physiol Gastrointest Liver Physiol (2009) 0.92
Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation. Ann Surg Oncol (2008) 0.92
Angiogenesis and antiangiogenic strategies in pancreatic cancer. Int J Gastrointest Cancer (2003) 0.91
Gene expression and promoter methylation of the XIAP-associated Factor 1 in renal cell carcinomas: correlations with pathology and outcome. Cancer Lett (2007) 0.91
1,2-Bis(4-nitro-benz-yl)diselane. Acta Crystallogr Sect E Struct Rep Online (2011) 0.91
Restoration of XAF1 expression induces apoptosis and inhibits tumor growth in gastric cancer. Int J Cancer (2009) 0.90
The XAF1 tumor suppressor induces autophagic cell death via upregulation of Beclin-1 and inhibition of Akt pathway. Cancer Lett (2011) 0.89
Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer. Regul Pept (2012) 0.88
Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta Oncol (2008) 0.86
Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas. Diagn Mol Pathol (2007) 0.86
Switch to full-length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor. Int J Cancer (2006) 0.84
Bone marrow-derived myofibroblasts promote colon tumorigenesis through the IL-6/JAK2/STAT3 pathway. Cancer Lett (2013) 0.84
E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J Gene Med (2009) 0.83
Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis (2005) 0.80
Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis. Cancer Gene Ther (2006) 0.80
Identification of a functional p53 responsive element within the promoter of XAF1 gene in gastrointestinal cancer cells. Int J Oncol (2010) 0.78
Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer (1998) 0.77
XIAP-associated factor 1 (XAF1) suppresses angiogenesis in mouse endothelial cells. Tumour Biol (2008) 0.76